Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of “Buy” by Analysts

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) have received a consensus recommendation of “Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have covered the stock in the last year is $30.50.

A number of research firms have weighed in on TYRA. UBS Group assumed coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Tuesday, February 18th.

Tyra Biosciences Trading Down 2.3 %

Shares of TYRA stock opened at $10.69 on Friday. The firm has a fifty day simple moving average of $13.05 and a 200-day simple moving average of $16.72. The company has a market capitalization of $540.95 million, a PE ratio of -6.64 and a beta of 1.09. Tyra Biosciences has a twelve month low of $9.93 and a twelve month high of $29.60.

Insider Buying and Selling

In other Tyra Biosciences news, Director Nina S. Kjellson sold 7,779 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $16.29, for a total value of $126,719.91. Following the sale, the director now directly owns 447,857 shares of the company’s stock, valued at $7,295,590.53. This trade represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 21,998 shares of company stock worth $344,818 over the last quarter. 15.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Tyra Biosciences

A number of hedge funds have recently made changes to their positions in TYRA. Rhumbline Advisers increased its position in Tyra Biosciences by 4.1% in the 4th quarter. Rhumbline Advisers now owns 26,202 shares of the company’s stock valued at $364,000 after acquiring an additional 1,027 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of Tyra Biosciences during the fourth quarter valued at $31,000. Bank of New York Mellon Corp raised its stake in shares of Tyra Biosciences by 5.2% during the fourth quarter. Bank of New York Mellon Corp now owns 45,007 shares of the company’s stock valued at $626,000 after purchasing an additional 2,221 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Tyra Biosciences by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock worth $132,000 after purchasing an additional 3,236 shares during the period. Finally, US Bancorp DE bought a new position in Tyra Biosciences in the 4th quarter valued at about $50,000. Institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.